We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Beats on Q1 Earnings & Sales Estimates
Read MoreHide Full Article
Involved in Scientific Research? Then you must have heard about MA-based Thermo Fisher Scientific, Inc. (TMO - Free Report) one of the leading scientific instrument manufacturers across the world. Interestingly for this acquisition-friendly company, the latest buy out of Life Technologies is expected to give birth to an unrivaled market leader serving research, Specialty Diagnostics and applied markets.
Currently, Thermo Fisher has a Zacks Rank #3 (Hold) but that could change following its promising first-quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate is pegged at $2.02 per share. Thermo Fisher’s adjusted earnings per share of $2.08 (up 16% year-over-year) in the reported quarter beat this estimate by 3%.
Thermo Fisher Scientific Inc Price and EPS Surprise
Revenues: Thermo Fisher posted first quarter revenues of $4.77 billion in, which has also surpassed the Zacks Consensus Estimate for revenues of $4.68 billion.
Key Stats: Among its four business segments in the reported quarter, Thermo Fisher delivered revenues of $1.36 billion (up 12%) in Life Sciences Solutions, $1.05 billion (up 39%) in Analytical Instruments, $866 million (up 1%) in Specialty Diagnostics and $1.70 billion (up 3%) in Laboratory Products and Services respectively. However on a full-year basis all the four segments have seen increase year-over-year.
Major Factors: Management seemed upbeat about its impressive first quarter results. The company delivered robust performance on both the top and bottom line on the back of its successful execution of growth strategy plan. Thermo Fisher is currently working on innovations and launching new products in laboratory market. In Asia-Pacific and emerging markets, the company has also leveraged its industry-leading scale to drive strong growth, especially in China.
Stock Price: Following the earnings release, share prices rose 0.74% in the pre-market trading session.
Check back later for our full write up on this Thermo Fisher earnings report later!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Thermo Fisher (TMO) Beats on Q1 Earnings & Sales Estimates
Involved in Scientific Research? Then you must have heard about MA-based Thermo Fisher Scientific, Inc. (TMO - Free Report) one of the leading scientific instrument manufacturers across the world. Interestingly for this acquisition-friendly company, the latest buy out of Life Technologies is expected to give birth to an unrivaled market leader serving research, Specialty Diagnostics and applied markets.
Currently, Thermo Fisher has a Zacks Rank #3 (Hold) but that could change following its promising first-quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate is pegged at $2.02 per share. Thermo Fisher’s adjusted earnings per share of $2.08 (up 16% year-over-year) in the reported quarter beat this estimate by 3%.
Thermo Fisher Scientific Inc Price and EPS Surprise
Thermo Fisher Scientific Inc Price and EPS Surprise | Thermo Fisher Scientific Inc Quote
Revenues: Thermo Fisher posted first quarter revenues of $4.77 billion in, which has also surpassed the Zacks Consensus Estimate for revenues of $4.68 billion.
Key Stats: Among its four business segments in the reported quarter, Thermo Fisher delivered revenues of $1.36 billion (up 12%) in Life Sciences Solutions, $1.05 billion (up 39%) in Analytical Instruments, $866 million (up 1%) in Specialty Diagnostics and $1.70 billion (up 3%) in Laboratory Products and Services respectively. However on a full-year basis all the four segments have seen increase year-over-year.
Major Factors: Management seemed upbeat about its impressive first quarter results. The company delivered robust performance on both the top and bottom line on the back of its successful execution of growth strategy plan. Thermo Fisher is currently working on innovations and launching new products in laboratory market. In Asia-Pacific and emerging markets, the company has also leveraged its industry-leading scale to drive strong growth, especially in China.
Stock Price: Following the earnings release, share prices rose 0.74% in the pre-market trading session.
Check back later for our full write up on this Thermo Fisher earnings report later!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>